Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Coya Therapeutics (COYA) Research & Development (2022 - 2025)

Coya Therapeutics' Research & Development history spans 4 years, with the latest figure at $2.9 million for Q3 2025.

  • For Q3 2025, Research & Development rose 31.16% year-over-year to $2.9 million; the TTM value through Sep 2025 reached $13.7 million, up 19.01%, while the annual FY2024 figure was $11.9 million, 115.68% up from the prior year.
  • Research & Development for Q3 2025 was $2.9 million at Coya Therapeutics, down from $3.7 million in the prior quarter.
  • Across five years, Research & Development topped out at $5.2 million in Q1 2025 and bottomed at $708032.0 in Q4 2022.
  • The 4-year median for Research & Development is $1.6 million (2023), against an average of $2.2 million.
  • The largest annual shift saw Research & Development decreased 26.21% in 2023 before it soared 327.56% in 2024.
  • A 4-year view of Research & Development shows it stood at $708032.0 in 2022, then surged by 127.34% to $1.6 million in 2023, then rose by 20.37% to $1.9 million in 2024, then soared by 50.55% to $2.9 million in 2025.
  • Per Business Quant, the three most recent readings for COYA's Research & Development are $2.9 million (Q3 2025), $3.7 million (Q2 2025), and $5.2 million (Q1 2025).